Drug Profile

Aprepitant/Pramipexole - Alto Neuroscience

Alternative Names: ALTO-208; CTC-413

Latest Information Update: 23 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chase Therapeutics
Class Antiparkinsonians; Benzothiazoles; Fluorobenzenes; Ketones; Morpholines; Small molecules; Triazoles
Mechanism of Action Dopamine D2 receptor agonists; Dopamine D3 receptor agonists; Neurokinin 1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Parkinson's disease

Most Recent Events

03 Jun 2025 Alto Neuroscience acquires Aprepitant/Pramipexole from Chase Therapeutics
03 Jun 2025 Chase Therapeutics has a patent protection for aprepitant/pramipexole
03 Jun 2025 Adverse events data from a phase IIa trial in Parkinson's disease released by Alto Neuroscience

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com